PTHR1 in osteosarcoma: Specific molecular mechanisms and comprehensive functional perspective.
PTHR1
oncogene
osteosarcoma
prognosis
targeted therapy
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
14
02
2021
received:
30
11
2020
accepted:
17
02
2021
pubmed:
7
3
2021
medline:
18
9
2021
entrez:
6
3
2021
Statut:
ppublish
Résumé
Osteosarcoma occurs largely in children and adolescents and is the most common primary malignant tumour of bone. Although surgical advances and neoadjuvant chemotherapy have made great strides in recent years, rates of local recurrence and lung metastasis remain high, with a plateau in overall survival during the past decade. It is thus urgent to explore the pathogenesis of osteosarcoma and identify potential therapeutic targets. Parathyroid hormone receptor 1 (PTHR1) belongs to the broad family of G protein-coupled receptors, binding both parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP, a paracrine factor). Previous studies have shown that in tissues and cells of osteosarcoma, expression of PTHR1 is markedly increased, correlating with aggressive biologic behaviour and a poor prognosis. PTHR1 expression also correlates closely with epigenetic regulation, transcriptional regulation, post-translational modification and protein interaction. Herein, we have summarized the latest research on the role played by PTHR1 in progression of osteosarcoma, assessing its clinical utility as a novel biomarker and its therapeutic ramifications.
Identifiants
pubmed: 33675132
doi: 10.1111/jcmm.16420
pmc: PMC8034476
doi:
Substances chimiques
Biomarkers, Tumor
0
PTH1R protein, human
0
Receptor, Parathyroid Hormone, Type 1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3175-3181Subventions
Organisme : Natural Science Foundation of Liaoning Province
ID : 2020-MS-058
Organisme : Shenyang Young and Middle-aged Scientific and Technological Innovation Talent Support Plan
ID : RC190456
Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Aging (Albany NY). 2020 Feb 9;12(4):3486-3501
pubmed: 32039832
Asia Pac J Clin Oncol. 2017 Apr;13(2):e104-e110
pubmed: 25870979
Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):621-638
pubmed: 30449545
Bone. 2015 Dec;81:104-111
pubmed: 26164475
Am J Physiol Endocrinol Metab. 2012 May 1;302(10):E1183-8
pubmed: 22338074
Pol Merkur Lekarski. 2017 Apr 21;42(250):158-164
pubmed: 28530214
Int J Mol Sci. 2020 Sep 23;21(19):
pubmed: 32977425
Endocrinology. 2016 Jan;157(1):141-9
pubmed: 26562265
Oncogene. 2015 May 28;34(22):2922-33
pubmed: 25043296
Oncogene. 2020 Oct;39(43):6719-6732
pubmed: 32963352
Genome Med. 2020 Sep 28;12(1):83
pubmed: 32988398
Neuropeptides. 2014 Dec;48(6):353-9
pubmed: 25278090
Mol Cancer. 2018 May 12;17(1):89
pubmed: 29753317
J Cell Mol Med. 2021 Apr;25(7):3175-3181
pubmed: 33675132
Nat Rev Endocrinol. 2015 Dec;11(12):712-24
pubmed: 26303600
Biomaterials. 2018 Jul;171:230-246
pubmed: 29705656
Int J Mol Sci. 2019 Apr 04;20(7):
pubmed: 30987410
Cancer Epidemiol. 2015 Dec;39(6):956-63
pubmed: 26540607
Int J Biol Macromol. 2018 May;111:1255-1263
pubmed: 29366883
Clin Cancer Res. 2017 Oct 1;23(19):5824-5835
pubmed: 28659311
AMB Express. 2020 Jan 18;10(1):13
pubmed: 31955303
Eur J Endocrinol. 2010 May;162(5):979-86
pubmed: 20156969
Front Endocrinol (Lausanne). 2018 May 16;9:241
pubmed: 29867773
J Am Chem Soc. 2019 Sep 18;141(37):14486-14490
pubmed: 31496241
Expert Rev Anticancer Ther. 2016 May;16(5):543-56
pubmed: 26999418
Signal Transduct Target Ther. 2016 Mar 25;1:16001
pubmed: 29263893
Spine J. 2019 Dec;19(12):1941-1949
pubmed: 31306757
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5864-9
pubmed: 23533279
Int J Cancer. 2007 Sep 1;121(5):943-54
pubmed: 17410535
Neuroscience. 2020 Nov 21;449:189-201
pubmed: 32976983
Oncol Rep. 2016 Oct;36(4):1787-92
pubmed: 27499459
Nat Commun. 2016 Nov 18;7:13384
pubmed: 27857062
Biomed Pharmacother. 2019 Jun;114:108839
pubmed: 30978523
Matrix Biol. 2019 Jan;75-76:160-169
pubmed: 29106944
Hormones (Athens). 2017 Apr;16(2):150-160
pubmed: 28742503
J Exp Clin Cancer Res. 2020 Sep 4;39(1):178
pubmed: 32887645
Bioorg Med Chem Lett. 2019 Sep 15;29(18):2613-2616
pubmed: 31383587
J Cell Mol Med. 2021 Mar;25(6):2841-2850
pubmed: 33511766
J Orthop Surg Res. 2017 Nov 9;12(1):168
pubmed: 29121993
Cell Physiol Biochem. 2018;51(4):1695-1709
pubmed: 30504697
Bone. 2017 Dec;105:226-236
pubmed: 28935557
J Hematol Oncol. 2018 Feb 06;11(1):16
pubmed: 29409495
Trends Mol Med. 2017 Aug;23(8):737-755
pubmed: 28735817
J Cell Physiol. 2020 Jan 29;:
pubmed: 31994731
Clin Cancer Res. 2016 Dec 15;22(24):6129-6141
pubmed: 27342399
J Hematol Oncol. 2017 Jan 7;10(1):10
pubmed: 28061797
Clin Cancer Res. 2019 Nov 1;25(21):6346-6356
pubmed: 31175097
FEBS J. 2011 Oct;278(19):3782-92
pubmed: 21834878
World J Surg Oncol. 2017 Sep 21;15(1):177
pubmed: 28934958
Sci Rep. 2020 Jan 31;10(1):1564
pubmed: 32005896
Cell Tissue Res. 2021 Feb;383(2):707-722
pubmed: 32960354
J Natl Cancer Inst. 2019 Nov 1;111(11):1216-1227
pubmed: 30793158
DNA Cell Biol. 2019 Nov;38(11):1323-1337
pubmed: 31536386
Cells. 2020 Apr 15;9(4):
pubmed: 32326444
Int J Mol Sci. 2012;13(1):56-70
pubmed: 22312238
Nat Genet. 2002 Mar;30(3):306-10
pubmed: 11850620
Clin Cancer Res. 2017 Jul 15;23(14):3721-3733
pubmed: 28053020
J Orofac Orthop. 2014 May;75(3):226-39
pubmed: 24825834
Mol Cancer. 2019 Apr 2;18(1):73
pubmed: 30940151